Objectives

After participating in this educational activity, attendees should be able to:

1| Discuss the new nomenclature and the different categories of steatotic liver disease (SLD).
2| Describe the epidemiology of Metabolic Dysfunction-Associated SLD (MASLD)
3| Describe the current and future therapeutics for MASLD

Presenter(s): 
Naim Alkhouri, MD, FAASLD, DABOM
Chief Medical Officer, Chief of Transplant Hepatology,
Director of the Steatotic Liver Program
Arizona Liver Health
Associate Professor of Medicine and Pediatrics
University of Texas Health
 

Name of IndividualRoleFinancial Relationship DisclosuresDiscussion of
Unlabeled/Unapproved Uses of
Drugs/Devices in Presentation?
Naim Alkhouri, MD      Speaker    

 Dr. Alkhouri receives research funding from Madrigal, Novo Nordisk and Boehringer Ingelheim.  These relationships have been mitigated.

Any relevant relationships for this individual have been mitigated

Yes - Dr. Alkhouri will discuss off-label/investigative use of commercial products/devises.  

Any relevant relationships for this individual have been mitigated

The design and content of Baystate Continuing Interprofessional Education (CE) activities support quality improvement in healthcare and provide fair and balanced views of therapeutic options.  Any relevant financial relationships are mitigated prior to the educational activity.

None of the other planners or faculty for this educational event have commercial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Session date: 
04/29/2025 - 8:00am to 9:00am EDT
Location: 
Chestnut 1 A/B
759 Chestnut Street
Springfield, MA 01199
United States
See map: Google Maps
Add to calendar: 
  • 1.00 ACPE Contact Hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC Contact Hours
  • 1.00 IPCE Credit Hour(s)

Please login or register to take this course.